Cardio-oncology & otherCohort study
Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy–Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer
- Prospective cohort study
- single-centre
- biomarker study
Authors' conclusion
This study found that higher cardiomyocyte cfDNA level after completion of anthracycline chemotherapy was associated with risk of CTRCD.
Study context
- Population
- Patients with ERBB2-positive breast cancer treated with doxorubicin-based chemotherapy followed by trastuzumab (+/- pertuzumab), academic cancer center, July 2014–April 2016cohort of 80
- Participants
- 71 patients
- Exposure
- Patients who developed cancer therapy-related cardiac dysfunction (CTRCD) vs those who did not
- Outcome
- CTRCD (symptomatic HF or asymptomatic LVEF decline ≥10% from baseline to less than lower limit of normal or ≥16%), association with post-anthracycline cardiomyocyte cell-free DNA (cfDNA)
- Follow-up
- 1 year
Main finding
Post-anthracycline cardiomyocyte cfDNA level · post-anthracycline
Hazard ratio
1.02
95% CI 1.00–1.03
P = 0.046
By group
Cardiomyocyte cfDNA per 1-copy/mL increase
HR 1.02 (95% CI 1.00–1.03); P = 0.046
Per 1-copy/mL increase, as printed
As reported in the abstract
Observational data: associations, not effects.
Further findings
CTRCD incidence · 1 year
- Developed CTRCD
- Ten of 71 patients (14%)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Association of Circulating Cardiomyocyte Cell-Free DNA With Cancer Therapy–Related Cardiac Dysfunction in Patients Undergoing Treatment for ERBB2-Positive Breast Cancer. JAMA Cardiol. Published 1 July 2023. doi:10.1001/jamacardio.2023.1229
Summarised from the published abstract; every number is checked against it